Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 938 000 KRW -1.16%
Market Cap: 66.8T KRW
Have any thoughts about
Samsung Biologics Co Ltd?
Write Note

Samsung Biologics Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Samsung Biologics Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Samsung Biologics Co Ltd
KRX:207940
Accrued Liabilities
â‚©338.5B
CAGR 3-Years
28%
CAGR 5-Years
57%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Accrued Liabilities
â‚©631.2m
CAGR 3-Years
22%
CAGR 5-Years
11%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Accrued Liabilities
â‚©8.3B
CAGR 3-Years
66%
CAGR 5-Years
51%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Accrued Liabilities
â‚©906.5m
CAGR 3-Years
114%
CAGR 5-Years
29%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Accrued Liabilities
â‚©11.4B
CAGR 3-Years
241%
CAGR 5-Years
112%
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Accrued Liabilities
â‚©7.2B
CAGR 3-Years
N/A
CAGR 5-Years
132%
CAGR 10-Years
N/A
No Stocks Found

Samsung Biologics Co Ltd
Glance View

Market Cap
66.8T KRW
Industry
Life Sciences Tools & Services

In the bustling world of biopharmaceuticals, Samsung Biologics Co Ltd has carved a niche as a formidable player, merging cutting-edge technology with industrial scale to drive its operations. Situated in Incheon, South Korea, the company emerged as a key subsidiary of Samsung Group, bringing with it the organizational prowess and strategic vision that hallmark the conglomerate. Established with the goal of reshaping the global landscape of biopharmaceutical manufacturing, Samsung Biologics offers a suite of contract development and manufacturing organization (CDMO) services. From early-stage development to large-scale production, the company supports clients through every step of a biologic's lifecycle, ensuring seamless transition from laboratory to patient. The blend of state-of-the-art facilities and advanced process technologies enables them to meet the growing demands for complex biopharmaceuticals efficiently. Samsung Biologics' revenue machine spins around its comprehensive service spectrum, which includes drug substance and product manufacturing and laboratory testing services. The contract-based model allows global pharma companies to outsource crucial parts of their development and manufacturing processes to Samsung Biologics, thus optimizing costs and timelines. By building strategic partnerships and continuously investing in expanding its manufacturing capacity, Samsung Biologics not only captures market share but also aligns itself with the burgeoning demand for biosimilars and other next-generation therapeutics. Furthermore, operating within a highly regulated and competitive industry, the company's focus on maintaining stringent quality standards and regulatory compliance cements its reputation as a trusted partner in the pharmaceutical sector.

Intrinsic Value
490 513.26 KRW
Overvaluation 48%
Intrinsic Value
Price

See Also

What is Samsung Biologics Co Ltd's Accrued Liabilities?
Accrued Liabilities
338.5B KRW

Based on the financial report for Sep 30, 2024, Samsung Biologics Co Ltd's Accrued Liabilities amounts to 338.5B KRW.

What is Samsung Biologics Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
57%

Over the last year, the Accrued Liabilities growth was 19%. The average annual Accrued Liabilities growth rates for Samsung Biologics Co Ltd have been 28% over the past three years , 57% over the past five years .

Back to Top